Clinical trials: Small Cell
Leukemia
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Primary Objectives: 1. Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of oxaliplatin in combination with fludarabine, Ara-C and rituximab in patients with Richter's transformation, prolymphocytic…
- Trial name
- NCT00452374
- Testing
- Cytarabine, Fludarabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Non-Small Cell Lung Cancer
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and…
- Trial name
- NCT00732303
- Testing
- Pemetrexed, Radiation Therapy
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hoosier Cancer Research Network
Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer…
- Conditions
- Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
- Trial name
- NCT02274038
- Testing
- Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Adenocarcinomas, Neuroendocrine Tumors
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose…
- Conditions
- Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
- Trial name
- NCT01970540
- Testing
- lurbinectedin (PM01183), Doxorubicin
- Where
- 7 sites in Spain, United Kingdom
- Volunteers
- 122 people
- Sponsor
- PharmaMar
Nonsmall Cell Lung Cancer, NSCLC
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following…
- Trial name
- NCT02973789
- Testing
- NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
- Where
- 124 sites in United States, Austria and 16 more
- Volunteers
- 291 people
- Sponsor
- NovoCure GmbH
Carcinoma，Non-Small-Cell Lung
A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
This open-label, single-arm, multi-center study will evaluate the progression-free survival in participants with histologically documented, advanced and/or metastatic chemotherapy naive, non-small cell lung cancer (NSCLC) with…
- Trial name
- BIOTEC (NCT01153984)
- Testing
- Erlotinib
- Where
- 9 sites in Romania
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01408043
- Testing
- plerixafor, filgrastim, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.
- Trial name
- ELIOS (NCT03239340)
- Testing
- Osimertinib
- Where
- 26 sites in United States, Italy and 3 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Lung Cancer
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small…
- Trial name
- ASTRIS (NCT02474355)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 201 sites in Argentina, Australia and 14 more
- Volunteers
- 3,017 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had…
- Trial name
- NCT02706626
- Testing
- brigatinib
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Criterium, Inc.
CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia…
- Conditions
- CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01865617
- Testing
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Fred Hutchinson Cancer Center
Locally Advanced Non-Small Cell Lung Cancer
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
This is a phase I, open-label trial that will utilise a Time To Event Continual Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC.
- Trial name
- ARCADIAN (NCT04648033)
- Testing
- Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Oxford
Non-small Cell Lung Cancer
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs.
- Trial name
- NCT02730247
- Testing
- ramucirumab, nab-paclitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Liza Villaruz, MD
Carcinoma, Non-Small-Cell Lung Carcinoma
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
- Conditions
- Carcinoma, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms
- Trial name
- NCT00243347
- Testing
- AZD2171
- Where
- 2 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or…
- Trial name
- NCT02657434
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 578 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
The purpose of this study is to determine whether treatment with temozolomide will shrink small cell lung cancer tumors. Temozolomide is an oral chemotherapy drug that is currently used to treat brain cancer and melanoma.
- Trial name
- NCT00740636
- Testing
- Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer
Measure the 1 year survival of non small cell lung cancer (NSCLC) patients who are being treated with pemetrexed in combination with cisplatin and radiation.
- Trial name
- NCT00529100
- Testing
- Pemetrexed Phase 1, Cisplatin Phase 1, Radiation Therapy
- Where
- 4 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
- Trial name
- NCT00695292
- Testing
- irinotecan, Carboplatin, sunitinib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.